Future Directions in the Treatment of Osteosarcoma
Cells, 2021 Osteosarcoma is the most common primary bone sarcoma and is often diagnosed in the 2nd–3rd decades of life. Response to the aggressive and highly toxic neoadjuvant methotrexate-doxorubicin-cisplatin (MAP) chemotherapy schedule is strongly predictive of ...
A. Smrke +5 more
semanticscholar +1 more source
Journal of Bone Oncology, 2020 Background: Long noncoding RNAs (lncRNAs) have been identified as key players in promoting tumourigenesis in osteosarcoma. LncRNA OR3A4 (OR3A4) has been reported as an oncogene in a number of tumours.
Changcheng Yang +8 more
doaj +1 more source
MiR-138 Acts as a Tumor Suppressor by Targeting EZH2 and Enhances Cisplatin-Induced Apoptosis in Osteosarcoma Cells. [PDF]
PLoS ONE, 2016 Chemotherapeutic insensitivity remains a major obstacle to treating osteosarcoma effectively. Recently, increasing evidence has suggested that microRNAs (miRNAs) are involved in drug resistance. However, the effect of miR-138 on cisplatin chemoresistance
Ziqiang Zhu +5 more
doaj +1 more source
The disintegrin echistatin in combination with doxorubicin targets high-metastatic human osteosarcoma overexpressing ανβ3 integrin in chick embryo and nude mouse models. [PDF]
, 2016 Echistatin, a cyclic RGD peptide, which is an antagonist of αvβ3 integrin (disintegrin), inhibited human osteosarcoma in the chick chorioallontoic membrane (CAM) model and tumor growth and pulmonary metastases in a nude mouse orthotopic model.
Bouvet, Michael +6 more
core +4 more sources
ROCK2 Regulates Invasion and Migration of Osteosarcoma Cells
Zhongliu Fangzhi Yanjiu, 2022 Objective To analyze the expression of ROCK2 in osteosarcoma tissues and explore its effect on the invasion and migration of osteosarcoma cells and related mechanism.
SHAN Wenhao +4 more
doaj +1 more source
Mucoepidermoid carcinoma associated with osteosarcoma in a true malignant mixed tumor of the submandibular region [PDF]
, 2015 True malignant mixed tumor, also known as carcinosarcoma, is a rare tumor of the salivary gland composed of both malignant epithelial and malignant mesenchymal elements.
Cerbelli, B +4 more
core +3 more sources
DEPDC1 as a crucial factor in the progression of human osteosarcoma
Cancer Medicine, 2023 Objective Novel therapeutic strategies are emerging with the increased understanding of the underlying mechanisms of human osteosarcoma. This current study tends to decipher the potentially critical role of DEP domain‐containing 1 (DEPDC1), a tumor ...
Lin Shen +11 more
doaj +1 more source
Genetically engineered pre-microRNA-34a prodrug suppresses orthotopic osteosarcoma xenograft tumor growth via the induction of apoptosis and cell cycle arrest. [PDF]
, 2016 Osteosarcoma (OS) is the most common primary malignant bone tumor in children, and microRNA-34a (miR-34a) replacement therapy represents a new treatment strategy. This study was to define the effectiveness and safety profiles of a novel bioengineered miR-
Qiu, Jing-Xin +5 more
core +2 more sources
Osteosarcoma mechanobiology and therapeutic targets
British Journal of Pharmacology, 2021 Osteosarcoma is one of the most common primary tumours of the bone, with a 5‐year survival rate of less than 20% after the development of metastases. Osteosarcoma is highly predisposed in Paget's disease of the bone, and both have common characteristic ...
Z. Shoaib, T. Fan, J. Irudayaraj
semanticscholar +1 more source
Cancer Cell International, 2021 Background Osteosarcoma is the most common primary bone tumor in children and adolescents. However, some patients with osteosarcoma develop resistance to chemotherapy, leading to a poor clinical prognosis.
Hong-Bo Li +6 more
doaj +1 more source